Lymphocyte infiltration, expression of interleukin (IL) -1, IL-6 and expression of mutated breast cancer susceptibility gene-1 correlate with malignancy of canine mammary tumours

Journal of Comparative Pathology

Volumn 142, Issue 2-3, 2010, Pages 177-186

  Kim, J H ^a   Yu, C H ^a   Yhee, J Y ^a   Im, K S ^a   Sur, J H ^a  

^a Konkuk University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER GROWTH; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE MUTATION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; METASTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

ADENOMA; ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CARCINOMA; DISEASE PROGRESSION; DOG DISEASES; DOGS; FEMALE; GENES, BRCA1; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1; INTERLEUKIN-6; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; MAMMARY NEOPLASMS, ANIMAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77649272945     PISSN: 00219975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcpa.2009.10.023     Document Type: Article

References (42)

1. Ben-Baruch A. Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumour-microenvironment interactions. Breast Cancer Research 2003, 5:31-36.
2. Bertolini J.N., Benson E.M. The role of human interleukin-6 in B-cell isotype regulation and differentiation. Cellular Immunology 1990, 125:197-209.
3. Bower J.E., Ganz P.A., Aziz N., Fahey J.L. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosomatic Medicine 2002, 64:604-611.
4. Chin Y., Janseens J., Vandepitte J., Vandenbrande J., Opdebeek L., et al. Phenotypic analysis of tumour-infiltrating lymphocytes from human breast cancer. Anticancer Research 1992, 12:1463-1466.
5. Claus E.B., Schildkraut J.M., Thompson W.D., Risch N.J. The genetic attributable risk of breast and ovarian cancer. Cancer 1996, 77:2318-2324.
6. Coronella-Wood J.A., Hersh E.M. Naturally occurring B-cell responses to breast cancer. Cancer Immunology and Immunotherapy 2003, 52:715-738.
7. DeNardo D.G., Coussens L.M. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Research 2007, 9:212.
8. Deng C.X., Scott F. Role of the tumour suppressor gene Brca1 in genetic stability and mammary gland tumour formation. Oncogene 2000, 19:1059-1064.
9. Elaraj D.M., Weinreich D.M., Varghese S., Puhlmann M., Hewitt S.M., et al. The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clinical Cancer Research 2006, 12:1088-1096.
10. Fajardo L.F., Kwan H.H., Kowalski J., Prionas S.D., Allison A.C. Dual role of tumour necrosis factor-alpha in angiogenesis. American Journal of Pathology 1992, 140:539-544.
11. Gemma A., Takenaka K., Hosoya Y., Matuda K., Seike M., et al. Altered expression of several genes in highly metastatic subpopulations of a human pulmonary adenocarcinoma cell line. European Journal of Cancer 2001, 37:1554-1561.
12. + monocytic cells in the tumour stroma. International Journal of Cancer 1985, 35:199-205.
13. Hall J.M., Lee M.K., Newman B., Morrow J.E., Anderson L.A., et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990, 250:1684-1689.
14. Hampe J.F., Misdorp W. Tumours and dysplasias of the mammary gland. Bulletin of the World Health Organization 1974, 50:111-133.
15. Hill A.D., Doyle J.M., McDermott E.W., O'Higgins N.J. Hereditary breast cancer. British Journal of Surgery 1997, 84:1334-1339.
16. Hsiao Y.W., Liao K.W., Chung T.F., Liu C.H., Hsu C.D., et al. Interactions of host IL-6 and IFN-gamma and cancer-derived TGF-beta1 on MHC molecule expression during tumour spontaneous regression. Cancer Immunology and Immunotherapy 2008, 57:1091-1104.
17. Hsiao Y.W., Liao K.W., Hung S.W., Chu R.M. Tumour-infiltrating lymphocyte secretion of IL-6 antagonizes tumour-derived TGF-beta 1 and restores the lymphokine-activated killing activity. Journal of Immunology 2004, 172:1508-1514.
18. Jaiswal M., LaRusso N.F., Burgart L.J., Gores G.J. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Research 2000, 60:184-190.
19. Kim D.M., Koo S.Y., Jeon K., Kim M.H., Lee J., et al. Rapid induction of apoptosis by combination of flavopiridol and tumour necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines. Cancer Research 2003, 63:621-626.
20. Kishimoto T., Hirano T. Molecular regulation of B lymphocyte response. Annual Reviews in Immunology 1988, 6:485-512.
21. Kumar S., Kishimoto H., Chua H.L., Badve S., Miller K.D., et al. Interleukin-1 alpha promotes tumour growth and cachexia in MCF-7 xenograft model of breast cancer. American Journal of Pathology 2003, 163:2531-2541.
22. Lee W.Y., Jin Y.T., Chang T.W., Lin P.W., Su I.J. Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: a correlation with other biological parameters. Histopathology 1999, 34:106-112.
23. Liss C., Fekete M.J., Hasina R., Lam C.D., Lingen M.W. Paracrine angiogenic loop between head-and-neck squamous-cell carcinomas and macrophages. International Journal of Cancer 2001, 93:781-785.
24. O'Sullivan C., Lewis C.E. Tumour-associated leucocytes: friends or foes in breast carcinoma. Journal of Pathology 1994, 172:229-235.
25. Ramakrishnan R., Werbeck J., Khurana K.K., Khan S.A. Expression of interleukin-6 and tumour necrosis factor alpha and histopathologic findings in painful and non-painful breast tissue. Breast Journal 2003, 9:91-97.
26. Roldan G., Delgado L., Muse I.M. Tumoural expression of BRCA1, estrogen receptor alpha and ID4 protein in patients with sporadic breast cancer. Cancer Biology and Therapeutics 2006, 5:505-510.
27. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature 2001, 411:380-384.
28. Saijo Y., Tanaka M., Miki M., Usui K., Suzuki T., et al. Proinflammatory cytokine IL-1 beta promotes tumour growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumour-stromal interaction. Journal of Immunology 2002, 169:469-475.
29. Salven P., Hattori K., Heissig B., Rafii S. Interleukin-1alpha promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. FASEB Journal 2002, 16:1471-1473.
30. See D., Mason S., Roshan R. Increased tumour necrosis factor alpha (TNF-alpha) and natural killer cell (NK) function using an integrative approach in late stage cancers. Immunology Investigation 2002, 31:137-153.
31. Singer C.F., Kronsteiner N., Hudelist G., Marton E., Walter I. Interleukin 1 system and sex steroid receptor expression in human breast cancer: interleukin 1alpha protein secretion is correlated with malignant phenotype. Clinical Cancer Research 2003, 9:4877-4883.
32. Smith C.W., Chen Z., Dong G., Loukinova E., Pegram M.Y., et al. The host environment promotes the development of primary and metastatic squamous cell carcinomas that constitutively express proinflammatory cytokines IL-1alpha, IL-6, GM-CSF, and KC. Clinical and Experimental Metastasis 1998, 16:655-664.
33. Sorenmo K. Canine mammary gland tumours. Veterinary Clinics of North America: Small Animal Practice 2003, 33:573-596.
34. Sugiura T., Matsuyama S., Akiyosi H., Takenaka S., Yamate J., et al. Expression patterns of the BRCA1 splicing variants in canine normal tissues and mammary gland tumours. Journal of Veterinary Medical Science 2007, 69:587-592.
35. Tashbaeva R.E., Hwang D.N., Song G.S., Choi N.H., Lee J.H., et al. Cellular characterization of multidrug resistance P-glycoprotein, alpha fetoprotein, and neovascular endothelium-associated antigens in canine hepatocellular carcinoma and cirrhotic liver. Veterinary Pathology 2007, 44:600-606.
36. Thompson M.E., Jensen R.A., Obermiller P.S., Page D.L., Holt J.T. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nature Genetics 1995, 9:444-450.
37. + macrophages in antitumour cytotoxicity. Laboratory Investigation 1992, 67:166-174.
38. Wilson J., Balkwill F. The role of cytokines in the epithelial cancer microenvironment. Seminars in Cancer Biology 2002, 12:113-120.
39. Wink D.A., Kasprzak K.S., Maragos C.M., Elespuru R.K., Misra M., et al. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science 1991, 254:1001-1003.
40. Wong P.Y., Staren E.D., Tereshkova N., Braun D.P. Functional analysis of tumour-infiltrating leukocytes in breast cancer patients. Journal of Surgery Research 1998, 76:95-103.
41. Yang X., Lippman M.E. BRCA1 and BRCA2 in breast cancer. Breast Cancer Research and Treatment 1999, 54:1-10.
42. Yu J.L., Rak J.W. Host microenvironment in breast cancer development: inflammatory and immune cells in tumour angiogenesis and arteriogenesis. Breast Cancer Research 2003, 5:83-88.